ISRCTN38354847已完成未知
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy
axdale Ltd (UK)0 个研究点目标入组 0 人开始时间: 2003年2月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Written informed consent
- •2. Score of greater than or equal to 16 on the Hamilton Depression Rating Scale (HDRS)
- •3.Treatment for greater than or equal to 8 weeks with one or more standard antidepressant, at stable dose for greater than or equal to 3 weeks
- •4. Currently receiving at least the minimum therapeutic dose of one or more standard antidepressant, as defined in the British National Formulary (BNF)
- •5. Diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth edition [DSM-IV])
- •6. Male or female of any race aged 18-75
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in patients with a new or recurrent episode of depressioDepressionMental and Behavioural DisordersDepressive episodeISRCTN63565713axdale Ltd (UK)
已完成
不适用
A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose ranging pilot study of ethyl eicosapentaenoate (EPA) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapyDepressionMental and Behavioural DisordersISRCTN44366049axdale Ltd (UK)
已完成
不适用
A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophreniaMental and Behavioural DisordersSchizophreniaISRCTN44218911axdale Ltd (UK)
进行中（未招募）
不适用
Clinical study to investigate the efficacy and safety of an ointment that increases the blood circulation in the skin, containing 2.5% Nicoboxil and 0.4% Nonivamide, in comparison to ointments that contain only one of both compounds, or none of them (placebo) for the treatment of acute low back paiAcute low back painEUCTR2011-003890-27-DEBoehringer Ingelheim Pharma GmbH & Co. KG
进行中（未招募）
1 期
Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthmaAsthmaEUCTR2013-002345-11-GBAstraZeneca AB1,134